item management s discussion and analysis of financial condition and results of operations general the company has focused its efforts on three product lines external pumps and related disposables  implantable insulin pumps and continuous glucose monitoring systems 
there have been no sales of glucose monitoring systems to date 
sales activity of the implantable insulin pump  primarily in europe  where the product is approved for commercial distribution  is in an early stage 
results of operations the following table sets forth for the years indicated the percentage relationship to net sales of certain items in the company s consolidated statements of operations and the percentage changes in the dollar amounts of such items on a comparative basis 
annual increase decrease percentage of net sales vs 
vs 
net sales cost of sales gross profit operating expenses selling  general and administrative research and development total operating expenses operating income loss net sales the following table sets forth domestic and international net sales  gross profits and research and development expenditures related to the company s three primary product lines for the three years in the period ended december  dollars in thousands of net sales net sales external pumps and related disposables domestic    international    subtotal    implantable pumps domestic international   subtotal    other net sales total    gross profits external pumps and related disposables    implantable pumps  other total    research and development expenses external pumps and related disposables    implantable pumps    glucose monitoring systems    total    fiscal years ended december  and december  net sales 
net sales increased in over to  from  this increase is principally the result of an increase of  or  in the sales volume of external pumps and related disposables 
domestic sales of these products grew  or  from to  while international sales increased  or  the domestic sales increase was primarily the result of increased sales volume of external pumps and related disposables  with external pump sales growing at a rate in excess of disposable product sales 
additionally  net sales increased due to a customer shift to more expensive disposable products principally the sof set qr offered by the company since june  with enhanced features and commensurately higher sales prices 
with the introduction of the company s new model insulin pump in june  the domestic average sales prices on external pumps increased  while the related disposable products experienced relative price stability 
international sales of external pumps and related disposables for and include the sale of external pumps to novo nordisk a s  which previously manufactured an external insulin pump and related disposables that were sold in europe 
under an agreement with the company entered into in late  the external insulin pumps that novo nordisk previously manufactured and sold were replaced with the company s external insulin pumps 
sales of external pumps to novo nordisk represented of international sales of external pumps and related disposables in  while such sales represented of international sales of these products in the decline in sales to novo nordisk in reflects the completion of the contractually determined delivery schedule with novo nordisk during the quarter ended june  sales of implantable pumps decreased by  or  in over due to problems encountered with the special insulin formulation manufactured by hoechst and used in the implantable pump  such sales were limited during although the company received certification under the applicable directives issued by the eu and received the ce mark in march for the implantable pump permitting commercial sale throughout the eu  separate approval from the eu is required for commercial sale of the insulin 
hoechst  the manufacturer of that insulin  has applied for such approval 
such approval has not yet been received and no assurance can be given that such approval will be received 
future sales of the company s implantable insulin pumps may be adversely affected by the lack of availability of the special insulin utilized in the implantable pump  as well as any delay or denial of regulatory approval for the insulin  seasonality  and overall market acceptance of this product line 
the company and hoechst are continuing their testing of the special insulin for use in the implantable pump 
no assurance can be given as to the potential for success of these efforts 
if such efforts are not successful  the business  results of operations or financial condition of the company could be materially adversely affected 
in order for the implantable pump to be authorized for sale in the us  the company must work with hoechst under a procedure established by the fda for approval of a combined application for the company s pump and the hoechst insulin 
the company has completed preparation of the pma element of the application for the implantable pump and is assisting hoechst in the preparation of the nda element of the application for this special insulin 
delay or failure to obtain fda approval could have a material adverse effect on the company s business  results of operations or financial condition 
see business products current products implantable insulin pump and business government regulation 
cost of sales and operating expenses 
cost of sales increased in over to  from  as a percentage of net sales  cost of sales decreased to in from in increased sales volume enabled the company to spread its fixed manufacturing costs over a larger sales base and thereby achieve certain economies of scale 
the company has continued to implement manufacturing efficiency programs that reduced per unit labor  overhead and materials costs 
additionally  the company achieved lower product costs for certain disposable products by bringing the manufacturing processes in house during cost of sales in included manufacturing start up expenses related to the company s june release of its latest generation external insulin pump  the model gross margins on the external pumps and related disposables increased to of sales in  compared to in the company s gross profits have been adversely impacted by the implantable pump product line during due to continued unpredictable sales  which have inhibited the company s ability to realize manufacturing efficiencies on this product line 
the company expects this trend to continue for the foreseeable future 
selling  general and administrative expenses increased in over to  from  as a percentage of net sales  these expenses decreased to in from in selling  general and administrative expenses increased primarily due to higher external pump and related disposable sales volume  the introduction of the model external insulin pump  increased efforts to educate patients  professionals and payors in the intensive management of diabetes  and increased spending in international sales and marketing operations 
increased international expenses related primarily to bringing in house to the company s french subsidiary certain administrative functions that had been previously performed by a third party and the organizational and continuing start up costs of the company s german subsidiary  which was formed in december research and development expenses increased in over to  from  as a percentage of sales  research and development expenses decreased to in from in the increase in expenses is primarily the result of greater resources directed to the design and introduction of the company s model external insulin pump and increased development of the continuous glucose monitoring systems 
expenses related to the implantable insulin pump product line decreased in  as the company awaited approval of the special insulin required for this product 
the company anticipates that future research and development expenditures will include amounts for the further development of the company s existing technologies for use in other medical conditions 
other 
other income for and consists primarily of interest income generated from the company s cash  cash equivalents  and short term investment balances 
the company incurred interest expense in and no interest expense was incurred  however  during as all debt had been retired in connection with the company s july initial public offering 
the company s effective tax rate for has been computed giving consideration to the pretax earnings and losses applicable to the company s foreign and domestic tax jurisdictions and a continual decrease in the company s valuation allowance against net deferred tax assets due to improved operating results 
during  the company utilized all of its net operating loss carryforwards 
the company anticipates that future income tax rates for financial statement purposes will be lower than statutory state and federal income tax rates  as future income tax payments will be offset by the recognition of deferred income tax assets related to differences between financial reporting and income tax reporting requirements 
the company has not incurred any material foreign income tax expense to date 
inflation has not significantly impacted the company s results of operations for the past three years 
fiscal years ended december  and december  net sales 
net sales increased in over to  from  the growth in net sales of external pumps and related disposables amounted to  or  over such sales in due to growth in both the domestic and international markets 
domestic sales of these products grew  or  from to  while international net sales increased  or  the domestic net sales increase for resulted from increased sales volume of external pumps and related disposables  with disposable sales growing at a rate in excess of external pump sales 
the effect of the increased sales volume achieved in was somewhat offset by lower average sales prices obtained on the sale of pumps 
however  the related disposable products experienced a price increase during domestic sales of external insulin pumps to previous pump users continued to decrease as a percentage of total domestic sales 
as a result of this trend  the overall installed base of pump users increased at a faster rate than in prior periods 
the international net sales increase was primarily the result of increased sales volume of pumps and related disposables to foreign distributors 
the increase in international sales volume was partially offset by a scheduled decrease in sales under the company s contract with novo nordisk 
sales of external insulin pumps to novo nordisk represented of international sales of external pumps and related disposables in  while such sales represented of international sales of these products in sales of implantable pumps increased by  or  in over due to problems encountered with the special insulin formulation manufactured by hoechst and used in the implantable pump  such sales were limited to replacements for existing patients during the last half of and the first half of new patient implants for europe slowly recommenced in the second half of when the company received certification under the applicable directives issued by the eu and received the ce mark in march for the implantable pump 
cost of sales and operating expenses 
cost of sales increased in over to  from  as a percentage of net sales  cost of sales in decreased to from in increased sales volume enabled the company to spread its fixed manufacturing costs over a larger sales base 
gross margins on the primary product line increased to of sales in  compared to for this product line in gross margins on the implantable pump product line were positive for due to the increased sales  compared to negative gross margins on the implantable pump in selling  general and administrative expenses increased in over to  from  as a percentage of net sales  these expenses increased to in from in higher sales volume in was the most significant factor in the increase in selling expenses  primarily attributable to increased commissions and other variable costs related to the field sales force 
additional increases in selling expenses relate to the company s increased focus upon training and education of patients  health care professionals and third party payors 
general and administrative expenses also increased in over these increased costs related primarily to the development of the company s accounting  finance  mis  legal and human resources departments to support the company s growth and the requirements as a public reporting company 
research and development expenses increased in over to  from  as a percentage of sales  research and development expenses increased to in from in the increase is primarily the result of greater resources directed to all of the company s product lines 
the company increased research and development expenses related to the external pump and disposables to further the development of its next generation external insulin pump and several new disposable products 
increased research and development expenses were also incurred for the implantable pump and the continuous glucose monitoring systems 
other 
interest expense in and related to a  note payable retired in with proceeds from the company s initial public offering 
other income in and related primarily to interest income generated from the company s cash  cash equivalents  and short term investments balances  with the increase related to increased funds available as a result of the initial public offering 
liquidity and capital resources during the years ended and  the company used cash in operations of  and  respectively 
while the company was profitable in both years  the company s operating activities used cash  as receivables and inventories increased significantly 
the receivables increase relates to several factors  including the extension of more favorable credit terms for some key distributors  increased sales to be reimbursed to the company by third party payors which typically have longer collection cycles and the overall sales volume increase 
because the company experienced some product shortages during  primarily related to its disposable products  the company increased inventories in and to better serve its customers 
the company believes that maintaining increased inventories of these products and other key components will enable the company to better meet customer demands 
expenditures on inventories have also increased in as a result of the company s purchases of significant quantities of component parts for the implantable insulin pump under a supply agreement entered into in capital expenditures were   and  for   and respectively 
the company s capital expenditures consisted primarily of the purchase and improvement of its operating facilities 
the company s capital expenditures included continued building improvements  manufacturing expansion  the acquisition of additional research and development engineering equipment and information systems requirements 
the company anticipates that future capital expenditures will increase because of required repairs and upgrades to its principal facility in compliance with recently enacted building code provisions applicable to earthquake protection 
capital expenditures will also increase due to the purchase of manufacturing and other equipment associated with expanding the company s product lines and bringing more manufacturing in house  as well as the purchase of additional information systems equipment 
the company completed its initial public offering of common stock in which generated net proceeds of million 
there were no significant equity transactions during on january   the company entered into an unsecured line of credit agreement which enables the company to borrow up to million through january  the line of credit  if used  bears interest at an adjustable rate based upon certain commercial paper rates 
the rate on such line of credit was as of february  the company is required to maintain certain cash  net worth and debt conditions under the provisions of the credit agreement 
the company is currently in compliance with all of these conditions 
management expects that the current level of cash and cash equivalents will be sufficient to meet its cash needs for working capital and capital expenditures for at least one year 
however the requirements for additional capital and working capital are subject to change and will depend upon numerous factors  including the level of capital expenditures  research and development activities and results  competitive and technological developments  health care reimbursement trends  and the availability for acquisition by the company of complementary additional distribution channels  products  and technologies 
the company also is involved in certain litigation  the financial impact of which is uncertain 
see notes to consolidated financial statements and legal proceedings 
quarterly results the following table sets forth certain selected consolidated financial information of the company for its eight most recent quarters 
in the opinion of management  this unaudited financial information has been prepared on the same basis as the audited financial information  and includes all adjustments consisting only of normal  recurring adjustments necessary to present this information fairly when read in conjunction with the company s consolidated financial statements and notes thereto contained elsewhere in this report 
three months ended mar 
 june  sept 
 dec 
 mar 
 june  sept 
 dec 
 net sales         cost of sales         gross profit         operating expenses selling  general and administrative         research and development         total operating expenses         operating income loss     the company s results of operations have historically fluctuated on a quarterly basis 
these seasonal trends have resulted in sales and earnings for each of the first three quarters of a given year being less than sales and earnings for the fourth quarter of the preceding year 
these fluctuations have and will continue to result from numerous factors  including i practices of insurance companies and other third party payors with respect to reimbursement for the company s products  which tends to result in increased sales of the company s external infusion pumps later in the calendar year  after patients deductibles are satisfied  ii market acceptance of the company s products  iii timing of regulatory approvals  iv new product introductions  v competition  vi the company s ability to manufacture its products efficiently and vii timing of research and development expenditures 

